DexCom (DXCM) Financial Analysis & Valuation | Quarter Chart
DexCom (DXCM)
DXCMPrice: $69.98
Fair Value: 🔒
🔒score
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its... more
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of... more
Description
Shares
| Market Cap | $27.00B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Jacob Steven Leach |
| IPO Date | 2005-04-14 | CAGR | — |
| Employees | 10,200 | Website | www.dexcom.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 2.05% | Total Yield | 2.05% |
DXCM chart loading...
Fundamentals
Technicals
| Enterprise Value | $23.63B | P/E Ratio | 30.03 |
| Forward P/E | 22.7 | PEG Ratio | 0.33 |
| P/S Ratio | 5.44 | P/B Ratio | 8.84 |
| P/CF Ratio | 14.68 | P/FCF Ratio | 18.33 |
| EPS | $2.33 | EPS Growth 1Y | 74.63% |
| EPS Growth 3Y | 234.29% | EPS Growth 5Y | 249.25% |
| Revenue Growth 1Y | 16.15% | Gross Margin | 0.62% |
| Operating Margin | 0.21% | Profit Margin | 0.19% |
| ROE | 0.34% | ROA | 0.14% |
| ROCE | 0.23% | Current Ratio | 1.95 |
| Quick Ratio | 1.64 | Cash Ratio | 0.5 |
| Debt/Equity | 0.47 | Interest Coverage | 75.99 |
| Altman Z Score | 6.58 | Piotroski Score | 8 |